Free Trial

12,198 Shares in Pfizer Inc. (NYSE:PFE) Purchased by Liberty Wealth Management LLC

Pfizer logo with Medical background

Key Points

  • Liberty Wealth Management LLC has acquired 12,198 shares of Pfizer Inc. valued at approximately $309,000, marking a significant investment in the biopharmaceutical company.
  • Several institutional investors have dramatically increased their stakes in Pfizer, with Pacer Advisors Inc. raising its stake by 856.8% in the first quarter, now holding over 20 million shares.
  • Pfizer's stock currently has an average rating of "Moderate Buy" from analysts, with a price target of $28.28, as various analysts issue updates following recent earnings reports.
  • Five stocks we like better than Pfizer.

Liberty Wealth Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 12,198 shares of the biopharmaceutical company's stock, valued at approximately $309,000.

Several other large investors also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. raised its stake in shares of Pfizer by 856.8% during the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after acquiring an additional 17,957,928 shares in the last quarter. Starboard Value LP bought a new position in Pfizer in the fourth quarter worth approximately $407,730,000. Assenagon Asset Management S.A. increased its holdings in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after purchasing an additional 7,581,030 shares during the period. APG Asset Management N.V. increased its holdings in Pfizer by 1,106.0% during the 4th quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company's stock worth $143,967,000 after purchasing an additional 5,153,257 shares during the period. Finally, AQR Capital Management LLC raised its position in Pfizer by 299.5% during the 4th quarter. AQR Capital Management LLC now owns 6,698,797 shares of the biopharmaceutical company's stock valued at $177,719,000 after purchasing an additional 5,021,915 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Citigroup increased their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Bank of America upped their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. Finally, Morgan Stanley increased their price objective on shares of Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $28.28.

Check Out Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of Pfizer stock opened at $23.49 on Monday. The company has a 50 day moving average price of $24.36 and a 200 day moving average price of $24.55. The firm has a market capitalization of $133.55 billion, a P/E ratio of 17.02, a PEG ratio of 0.85 and a beta of 0.52. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is presently 124.64%.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Pfizer Right Now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines